Submitted:
19 October 2023
Posted:
20 October 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Study site and population
2.2. Sample collection
2.3. Determination of urinary arsenic concentrations
2.4. Determination of serum 25(OH)D concentrations
2.5. Determination of blood glucose concentrations
2.6. Quality assurance and quality control
2.7. Statistical analysis
3. Results
3.1. Basic characteristics of the study participants
3.2. Multivariate linear regression analysis between urinary arsenic species and serum 25(OH)D
3.3. Associations between urinary arsenic species and vitamin D status
3.4. Association between arsenic metabolism efficiency and serum vitamin D
3.5. Association between urinary arsenic species and serum 25 (OH)D in subgroups stratified by skin hyperkeratosis
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Acknowledgments
Conflicts of Interest
References
- Wilson, L.R., et al.; et al. Vitamin D deficiency as a public health issue: using vitamin D2 or vitamin D3 in future fortification strategies. . Proc Nutr Soc, 2017, 76, 392–399. [Google Scholar] [CrossRef]
- Heaney, R.P. Vitamin D in health and disease. Clin J Am Soc Nephrol, 2008, 3, 1535–41. [Google Scholar] [CrossRef]
- Rosen, C.J. and C.L. Taylor. Common misconceptions about vitamin D--implications for clinicians. Nat Rev Endocrinol, 2013, 9, 434–8. [Google Scholar] [CrossRef] [PubMed]
- Alshahrani, F. and N. Aljohani. Vitamin D: deficiency, sufficiency and toxicity. Nutrients, 2013, 5, 3605–16. [Google Scholar] [CrossRef]
- Holick, M.F. , Vitamin D deficiency. N Engl J Med, 2007, 357, 266–81. [Google Scholar] [CrossRef]
- Nair, P., B. Venkatesh. Vitamin D deficiency and supplementation in critical illness-the known knowns and known unknowns. Crit Care, 2018, 22, 276. [Google Scholar] [CrossRef]
- Marcinowska-Suchowierska, E., et al. , Vitamin D Toxicity-A Clinical Perspective. Front Endocrinol (Lausanne) 2018, 9, 550. [Google Scholar] [CrossRef]
- Tsiaras, W.G. and M.A. Weinstock. Factors influencing vitamin D status. Acta Derm Venereol 2011, 91, 115–24. [Google Scholar] [CrossRef]
- Meza-Meza, M.R., A.I. Ruiz-Ballesteros, and U. de la Cruz-Mosso. Ruiz-Ballesteros, and U. de la Cruz-Mosso, Functional effects of vitamin D: From nutrient to immunomodulator. Crit Rev Food Sci Nutr, 2022, 62, 3042–3062. [Google Scholar] [CrossRef]
- Mousavi, S.E., et al. Air pollution, environmental chemicals, and smoking may trigger vitamin D deficiency: Evidence and potential mechanisms. Environ Int, 2019, 122, 67–90. [Google Scholar] [CrossRef]
- Hoseinzadeh, E., et al. The impact of air pollutants, UV exposure and geographic location on vitamin D deficiency. Food Chem Toxicol, 2018, 113, 241–254. [Google Scholar] [CrossRef] [PubMed]
- Bimonte, V.M., et al. , The endocrine disruptor cadmium: a new player in the pathophysiology of metabolic diseases. J Endocrinol Invest, 2021, 44, 1363–1377. [Google Scholar] [CrossRef]
- Nogawa, K., et al. Mechanism for bone disease found in inhabitants environmentally exposed to cadmium: decreased serum 1 alpha, 25-dihydroxyvitamin D level. Int Arch Occup Environ Health, 1987, 59, 21–30. [Google Scholar] [CrossRef] [PubMed]
- Nogawa, K., et al. Serum vitamin D metabolites in cadmium-exposed persons with renal damage. Int Arch Occup Environ Health, 1990, 62, 189–93. [Google Scholar] [CrossRef] [PubMed]
- Arbuckle, T.E., et al. Maternal and fetal exposure to cadmium, lead, manganese and mercury: The MIREC study. Chemosphere, 2016, 163, 270–282. [Google Scholar] [CrossRef] [PubMed]
- Rosen, J.F., et al. , Reduction in 1,25-dihydroxyvitamin D in children with increased lead absorption. N Engl J Med, 1980, 302, 1128–31. [Google Scholar] [CrossRef] [PubMed]
- Garbinski, L.D., B.P. Rosen, and J. Chen. Pathways of arsenic uptake and efflux. Environ Int, 2019, 126, 585–597. [Google Scholar] [CrossRef]
- Zhao, J., et al. The association of arsenic exposure with hypertension and blood pressure: A systematic review and dose-response meta-analysis. Environ Pollut, 2021, 289, 117914. [Google Scholar] [CrossRef]
- Oremland, R.S. and J.F. Stolz. The ecology of arsenic. Science 2003, 300, 939–44. [Google Scholar] [CrossRef]
- Kumagai, T., et al. 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia. Cancer Res, 2005, 65, 2488–97. [Google Scholar] [CrossRef]
- Zamoiski, R.D., et al. Association of arsenic and metals with concentrations of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D among adolescents in Torreón, Mexico. Environ Health Perspect, 2014, 122, 1233–8. [Google Scholar] [CrossRef]
- Fang, X., et al. Associations of urine metals and metal mixtures during pregnancy with cord serum vitamin D Levels: A prospective cohort study with repeated measurements of maternal urinary metal concentrations. Environ Int, 2021, 155, 106660. [Google Scholar] [CrossRef] [PubMed]
- Ameer, S.S., et al. , Exposure to Inorganic Arsenic Is Associated with Increased Mitochondrial DNA Copy Number and Longer Telomere Length in Peripheral Blood. Front Cell Dev Biol, 2016, 4, 87. [Google Scholar]
- Ventura-Lima, J., M.R. Bogo, and J.M. Monserrat. Arsenic toxicity in mammals and aquatic animals: a comparative biochemical approach. Ecotoxicol Environ Saf, 2011, 74, 211–8. [Google Scholar] [CrossRef] [PubMed]
- Gardner, R.M., et al. Arsenic methylation efficiency increases during the first trimester of pregnancy independent of folate status. Reprod Toxicol, 2011, 31, 210–8. [Google Scholar] [CrossRef] [PubMed]
- Zhang, M., et al. Association between arsenic (+3 oxidation state) methyltransferase gene polymorphisms and arsenic methylation capacity in rural residents of northern China: a cross-sectional study. Arch Toxicol, 2023, 97, 2919–2928. [Google Scholar] [CrossRef] [PubMed]
- Vahter, M.E. , Interactions between arsenic-induced toxicity and nutrition in early life. J Nutr, 2007, 137, 2798–804. [Google Scholar] [CrossRef]
- De Loma, J., et al. Elevated arsenic exposure and efficient arsenic metabolism in indigenous women around Lake Poopó, Bolivia. Sci Total Environ, 2019, 657, 179–186. [Google Scholar] [CrossRef]
- Bikle, D.D. Vitamin D metabolism and function in the skin. Mol Cell Endocrinol 2011, 347, 80–9. [Google Scholar] [CrossRef]
- DeLuca, H.F. , Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004, 80 6 Suppl, 1689s–96s. [Google Scholar] [CrossRef]
- Chen, T.C., et al. , Factors that influence the cutaneous synthesis and dietary sources of vitamin D. Arch Biochem Biophys, 2007, 460, 213–7. [Google Scholar] [CrossRef] [PubMed]
- Holick, M.F. , The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord, 2017, 18, 153–165. [Google Scholar] [CrossRef] [PubMed]
- Kennel, K.A., M.T. Drake, and D.L. Hurley. Vitamin D deficiency in adults: when to test and how to treat. Mayo Clin Proc, 2010, 85, 752–7. [Google Scholar] [CrossRef] [PubMed]
- Lou, Q., et al. Arsenic exposure elevated ROS promotes energy metabolic reprogramming with enhanced AKT-dependent HK2 expression. Sci Total Environ, 2022, 836, 155691. [Google Scholar] [CrossRef] [PubMed]
- Wiciński, M., et al.; et al. Impact of Vitamin D on Physical Efficiency and Exercise Performance-A Review. Nutrients 2019, 11. [Google Scholar] [CrossRef] [PubMed]
- Mazur, A., et al. Vitamin D and Vitamin D3 Supplementation during Photodynamic Therapy: A Review. Nutrients, 2022, 14. [Google Scholar]
- Jäpelt, R.B. and J. Jakobsen. Vitamin D in plants: a review of occurrence, analysis, and biosynthesis. Front Plant Sci, 2013, 4, 136. [Google Scholar]
- Cashman, K.D. and M. Kiely. EURRECA-Estimating vitamin D requirements for deriving dietary reference values. Crit Rev Food Sci Nutr, 2013, 53, 1097–109. [Google Scholar] [CrossRef]
- Castano, L., et al. 25(OH)Vitamin D Deficiency and Calcifediol Treatment in Pediatrics. Nutrients 2022, 14. [Google Scholar]
- Chen, H., et al. Prenatal arsenic exposure, arsenic metabolism and neurocognitive development of 2-year-old children in low-arsenic areas. Environ Int, 2023, 174, 107918. [Google Scholar] [CrossRef]
- Tseng, C.H. , A review on environmental factors regulating arsenic methylation in humans. Toxicol Appl Pharmacol, 2009, 235, 338–50. [Google Scholar] [CrossRef] [PubMed]
- Pierce, B.L., et al. Arsenic metabolism efficiency has a causal role in arsenic toxicity: Mendelian randomization and gene-environment interaction. Int J Epidemiol, 2013, 42, 1862–71. [Google Scholar] [CrossRef] [PubMed]
- Valenzuela, O.L., et al. Urinary trivalent methylated arsenic species in a population chronically exposed to inorganic arsenic. Environ Health Perspect, 2005, 113, 250–4. [Google Scholar] [CrossRef] [PubMed]
- Bangert, C., P.M. Brunner, and G. Stingl. Immune functions of the skin. Clinics in Dermatology, 2011, 29, 360–376. [Google Scholar] [CrossRef] [PubMed]
- Yu, H.S., W.T. Liao, and C.Y. Chai. Arsenic carcinogenesis in the skin. J Biomed Sci, 2006, 13, 657–66. [Google Scholar] [CrossRef] [PubMed]
- Wu, S., et al. The potential of Diosgenin in treating psoriasis: Studies from HaCaT keratinocytes and imiquimod-induced murine model. Life Sci, 2020, 241, 117115. [Google Scholar] [CrossRef] [PubMed]
- Lehmann, B., et al. , UVB-induced conversion of 7-dehydrocholesterol to 1alpha,25-dihydroxyvitamin D3 in an in vitro human skin equivalent model. J Invest Dermatol, 2001, 117, 1179–85. [Google Scholar] [CrossRef] [PubMed]
- Bikle, D.D., et al. 1,25-Dihydroxyvitamin D3 production by human keratinocytes. Kinetics and regulation. J Clin Invest 1986, 78, 557–66. [Google Scholar] [CrossRef]
| Characteristics | Value |
|---|---|
| Age, years, mean ± SD | 57.92 ± 10.80 |
| BMI, kg/m2, mean ± SD | 25.77 ± 4.01 |
| Gender, n (%) | |
| Man | 256 (33.7) |
| Woman | 506 (66.3) |
| Skin hyperkeratosis | |
| No | 495 (64.9) |
| Yes | 267 (35.1) |
| Occupations, n (%) | |
| Farmer | 657 (86.1) |
| Others | 105 (13.9) |
| Education, n (%) | |
| Primary and below | 269 (35.4) |
| Junior high school | 409 (53.6) |
| Senior high school and above | 84 (11) |
| Milk consumption, n (%) | |
| ≤1/week | 471 (61.8) |
| >1/week | 291 (38.2) |
| Urinary tAs, μg/L, median (P25-P75) | 69.81 (27.77-137.51) |
| Urinary iAs, μg/L, median (P25-P75) | 3.46 (0.83-14.67) |
| Urinary MMA, μg/L, median (P25-P75) | 4.78 (0.32-16.14) |
| Urinary DMA, μg/L, median (P25-P75) | 51.15 (19.00-102.93) |
| iAs%, median (P25-P75) | 9.94 (2.39-18.58) |
| MMA%, median (P25-P75) | 9.41 (1.60-16.88) |
| DMA%, median (P25-P75) | 78.48 (66.53-90.18) |
| Blood glucose, mmol/L, median (P25-P75) | 5.70 (5.10-6.70) |
| 25(OH)D, ng/mL, mean ± SD | 74.03 ± 22.67 |
| Exposure | Box-Cox transformed β (95%CI) | p-Value |
|---|---|---|
| tAs | ||
| Model 1 | 0.046 (0.020, 0.071) | < 0.01 |
| Model 2 | 0.044 (0.021, 0.067) | < 0.01 |
| Model 3 | 0.044 (0.020, 0.069) | < 0.01 |
| iAs | ||
| Model 1 | 0.330 (0.035, 0.624) | 0.028 |
| Model 2 | 0.155 (-0.115, 0.425) | 0.260 |
| Model 3 | 0.100 (-0.178, 0.377) | 0.482 |
| MMA | ||
| Model 1 | 0.447 (0.145, 0.748) | < 0.01 |
| Model 2 | 0.276 (0.001, 0.551) | 0.049 |
| Model 3 | 0.272 (-0.013, 0.556) | 0.061 |
| DMA | ||
| Model 1 | 0.057 (0.024, 0.089) | < 0.01 |
| Model 2 | 0.060 (0.031, 0.091) | < 0.01 |
| Model 3 | 0.062 (0.030, 0.094) | < 0.01 |
| Exposure | OR (95% CI) | p-Value |
|---|---|---|
| tAs | ||
| Model 1 | 1.004 (1.001, 1.007) | < 0.01 |
| Model 2 | 1.004 (1.001, 1.007) | 0.045 |
| iAs | ||
| Model 1 | 1.023 (0.986, 1.061) | 0.222 |
| Model 2 | 1.004 (0.966, 1.044) | 0.838 |
| MMA | ||
| Model 1 | 1.026 (0.988, 1.065) | 0.187 |
| Model 2 | 1.007 (0.967, 1.049) | 0.724 |
| DMA | ||
| Model 1 | 1.006 (1.001, 1.010) | 0.010 |
| Model 2 | 1.006 (1.001, 1.011) | 0.017 |
| Box-Cox transformed β (95%CI) b | p-value b | |
|---|---|---|
| iAs% a | ||
| < 10.19 | 0.015 (-0.027, 0.057) | 0.484 |
| ≥ 10.19 | 0.064 (0.032, 0.096) | < 0.01 |
| MMA% a | ||
| < 9.54 | 0.053 (0.012, 0.094) | 0.036 |
| ≥ 9.54 | 0.038 (0.006, 0.070) | 0.044 |
| DMA% a | ||
| < 78.15 | 0.046 (0.013, 0.078) | < 0.01 |
| ≥ 78.15 | 0.047 (0.006, 0.087) | 0.027 |
| Box-Cox transformed β (95%CI) a | ||||
|---|---|---|---|---|
| Exposure | Normal | p-Value | Skin hyperkeratosis | p-Value |
| tAs | 0.041 (0.013, 0.069) | < 0.01 | 0.046 (-0.007, 0.099) | 0.090 |
| iAs | 0.169 (-0.173, 0.511) | 0.332 | 0.592 (0.041, 1.143) | 0.035 |
| MMA | 0.425 (0.075, 0.776) | < 0.01 | 0.430 (-0.139, 0.999) | 0.138 |
| DMA | 0.054 (0.017, 0.090) | < 0.01 | 0.052 (-0.015, 0.119) | 0.129 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).